Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase III results reported for Labopharm's twice-daily tramadol/acetaminophen combination

April 6, 2009

New heat shock protein 90 inhibitors investigated for effects in Alzheimer's disease

April 6, 2009

Elan and Wyeth amend bapineuzumab phase III protocol

April 3, 2009

Mitsubishi Tanabe obtains research and development rights in Asia for EVP-6124

April 3, 2009

FDA places ICA-105665 on partial clinical hold

April 3, 2009

Novel fentanyl formulations are safe and efficacious in cancer pain

April 3, 2009

KAI initiates second phase II trial for KAI-1678 in neuropathic pain

April 2, 2009

Dexmedetomidine shows favorable pharmacokinetics for long-term sedation in renal failure patients

April 2, 2009

Acorda Therapeutics receives FDA refuse to file letter for Fampridine-SR NDA

April 1, 2009

Shire and GlaxoSmithKline to co-promote Vyvanse for adult ADHD

April 1, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...